Quest for the right Drug
קיו-ואר 50 QVAR 50 (BECLOMETASONE DIPROPIONATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
שאיפה : INHALATION
צורת מינון:
משאף : INHALER
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8. Undesirable effects A serious hypersensitivity reaction including oedema of the eye, face, lips and throat (angioedema) has been reported rarely. As with other inhalation therapy, paradoxical bronchospasm may occur after dosing. Immediate treatment with a short-acting bronchodilator should be initiated, Qvar should be discontinued immediately and an alternative prophylactic treatment introduced. Systemic effects of inhaled corticosteroids may occur, particularly with high doses prescribed for prolonged periods. These include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density and the occurrence of cataract and glaucoma. Commonly, when taking Qvar, hoarseness and candidiasis of the throat and mouth may occur. To reduce the risk of hoarseness and candida infection, patients are advised to rinse their mouth after using their inhaler. Based on the MedDra system organ class and frequencies, adverse events are listed in the table below according to the following frequency estimate: very common ( 1/10); common (1/100 to <1/10); Uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). MedDra – system organ class Frequency and Symptom Infections and infestations Common: Candidiasis in mouth and throat Immune system disorders Rare: Allergic reactions, angioedema in eyes, throat, lips and face Endocrine disorders Very rare: Adrenal suppression,*, growth retardation * (in children and adolescents), bone density decreased* Psychiatric Disorders Unknown: Psychomotor hyperactivity, sleep disorders, anxiety, depression, aggression, behavioural changes (predominantly in children) Nervous system disorders Uncommon: Headache, vertigo, tremor Eye disorders Uncommon: Vision, blurred (see also section 4.4) Very rare: Cataract,* glaucoma* Not known: Central serous retinopathy Respiratory, thoracic and mediastinal Common: Hoarseness, pharyngitis disorders Uncommon: Cough, increased asthma symptoms Rare: Paradoxical bronchospasm Gastrointestinal disorders Common: Taste disturbances Uncommon: Nausea Skin and subcutaneous tissue disorders Uncommon: Urticaria, rash, pruritus, erythema, purpura Musculoskeletal and connective tissue Very rare: Decrease bone mineral density disorders *Systemic reactions are a possible response to inhaled corticosteroids, especially when a high dose is prescribed for a prolonged time (see section 4.4 Special warnings and precautions for use). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
Bronchial asthma
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף